LLY

956.19

-1.64%↓

JNJ

221.61

-0.09%↓

ABBV

200.92

-1.19%↓

UNH

373.87

+1.76%↑

AZN

182.54

+0.47%↑

LLY

956.19

-1.64%↓

JNJ

221.61

-0.09%↓

ABBV

200.92

-1.19%↓

UNH

373.87

+1.76%↑

AZN

182.54

+0.47%↑

LLY

956.19

-1.64%↓

JNJ

221.61

-0.09%↓

ABBV

200.92

-1.19%↓

UNH

373.87

+1.76%↑

AZN

182.54

+0.47%↑

LLY

956.19

-1.64%↓

JNJ

221.61

-0.09%↓

ABBV

200.92

-1.19%↓

UNH

373.87

+1.76%↑

AZN

182.54

+0.47%↑

LLY

956.19

-1.64%↓

JNJ

221.61

-0.09%↓

ABBV

200.92

-1.19%↓

UNH

373.87

+1.76%↑

AZN

182.54

+0.47%↑

Начало・Списък с акции・Schrodinger Inc

Schrodinger Inc

Отворен

СекторЗдравеопазване

12.95 0.15

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

12.6

Максимум

13.26

Ключови измерители
By Trading Economics
Приходи	169M 136M
Продажби	33M 87M
EPS	-0.18
Марж на печалбата	155.644
Служители	850
EBITDA	67M 36M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+48.31% upside

Дивиденти
By Dow Jones
Следващи печалби	5.08.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	137M 964M
Предишно отваряне	12.8
Предишно затваряне	12.95

Настроения в новините

By Acuity

53%

47%

278 / 347 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

23.27 / 26.13 Подкрепа & съпротива

Schrodinger Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

7.05.2026 г., 23:58 ч. UTC

Печалби

OCBC's First-Quarter Net Profit Rose on Record Noninterest Income

7.05.2026 г., 22:57 ч. UTC

Печалби

Australia's Macquarie Beats Consensus With 30% Fiscal Year Profit Jump

7.05.2026 г., 23:52 ч. UTC

Печалби

CoreWeave Stock Dives on Weak Outlook -- Barrons.com

7.05.2026 г., 23:45 ч. UTC

Пазарно говорене

Nikkei May Decline Amid Middle East Uncertainty -- Market Talk

7.05.2026 г., 23:39 ч. UTC

Пазарно говорене

Gold Rises on Signs of Ongoing U.S.-Iran Tensions -- Market Talk

7.05.2026 г., 23:28 ч. UTC

Пазарно говорене

Australian Budget Set to Contain A$64B in Spending Cuts-- Market Talk

7.05.2026 г., 23:11 ч. UTC

Печалби

OCBC Group CEO: Well-Positioned to Navigate Uncertainties, Deliver Sustainable Long-Term Value >O39.SG

7.05.2026 г., 23:06 ч. UTC

Печалби

Oversea-Chinese Banking Corp. 1Q Net Interest Margin 1.76%, Down 28 Bps on Year >O39.SG

7.05.2026 г., 23:05 ч. UTC

Печалби

Oversea-Chinese Banking Corp.: Solid 1Q Performance Underpinned by Record Non-Interest Income >O39.SG

7.05.2026 г., 23:04 ч. UTC

Печалби

Oversea-Chinese Banking Corp. 1Q Non-Interest Income S$1.61B Vs. S$1.31B >O39.SG

7.05.2026 г., 23:03 ч. UTC

Печалби

Oversea-Chinese Banking Corp. 1Q Net Interest Income S$2.22B Vs. S$2.35B >O39.SG

7.05.2026 г., 23:03 ч. UTC

Печалби

Oversea-Chinese Banking Corp. 1Q Net S$1.97B Vs. Net S$1.88B >O39.SG

7.05.2026 г., 23:02 ч. UTC

Печалби

Oversea-Chinese Banking Corp. 1Q Total Income S$3.83B Vs. S$3.66B >O39.SG

7.05.2026 г., 23:00 ч. UTC

Пазарно говорене

Australia's Federal Budget Likely to Contain Significant Reforms -- Market Talk

7.05.2026 г., 22:45 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

7.05.2026 г., 22:45 ч. UTC

Пазарно говорене

Lyft Says Efforts to Service Waymo's AVs Are Underway -- Market Talk

7.05.2026 г., 22:42 ч. UTC

Печалби

Australia's Macquarie Beats Consensus With 30% FY Profit Jump

7.05.2026 г., 22:33 ч. UTC

Печалби

Придобивния, сливания и поглъщания

Gilead Stock Falls. A Massive Acquisition Spree Is Coming at a Cost. -- Barrons.com

7.05.2026 г., 22:32 ч. UTC

Печалби

Macquarie FY Total Customer Deposits A$221.5B Vs. A$177.7B>MQG.AU

7.05.2026 г., 22:31 ч. UTC

Печалби

Macquarie FY Return on Equity 14.0% Vs. 11.2%>MQG.AU

7.05.2026 г., 22:31 ч. UTC

Печалби

Macquarie: 68% of FY Income From International >MQG.AU

7.05.2026 г., 22:30 ч. UTC

Печалби

Macquarie Bank Year-End CET1 Level 2 Ratio 12.8%>MQG.AU

7.05.2026 г., 22:30 ч. UTC

Печалби

Macquarie Capital Surplus A$9.3B at March 31 Vs. A$9.5B a Year Earlier>MQG.AU

7.05.2026 г., 22:29 ч. UTC

Печалби

Macquarie CEO: Well-Positioned for Superior Medium-Term Performance>MQG.AU

7.05.2026 г., 22:28 ч. UTC

Печалби

Macquarie: Continues a Conservative Approach to Capital, Funding, Liquidity>MQG.AU

7.05.2026 г., 22:28 ч. UTC

Печалби

Macquarie: Continues to Maintain a Cautious Stance>MQG.AU

7.05.2026 г., 22:27 ч. UTC

Печалби

Macquarie: Decision Recognizes Prevailing Market Conditions>MQG.AU

7.05.2026 г., 22:27 ч. UTC

Печалби

Macquarie Has Not Purchased Shares Since Extending the Buyback>MQG.AU

7.05.2026 г., 22:26 ч. UTC

Печалби

Macquarie to End Share Buyback Extended in November>MQG.AU

7.05.2026 г., 22:25 ч. UTC

Печалби

Macquarie Commodities and Global Markets FY Net Profit Contribution A$4.2B, Up 49% on Year>MQG.AU

Сравнение с други в отрасъла

Ценова промяна

Schrodinger Inc Прогноза

Ценова цел

By TipRanks

48.31% нагоре

12-месечна прогноза

Среден 19.25 USD 48.31%

Висок 24 USD

Нисък 13 USD

Според 6 анализатори от Wall Street, предложили 12-месечна ценова цел за Schrodinger Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

6 ratings

Купи

Задържане

Продай

Според 6 анализатори, дали борсови рейтинги на Schrodinger Inc през последните 3 месеца.

Техническа оценка

By Trading Central

23.27 / 26.13Подкрепа & съпротива

Recent bearish events outweigh bullish events.

All events are bullish.

Настроение

By Acuity

278 / 347 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Schrodinger Inc

Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. It has a research collaboration and license agreement with Novartis AG to advance multiple development candidates. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.